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Anti-Müllerian hormone (AMH) is required for sexual differentiation in the fetus, and in 
adult females AMH is produced by growing ovarian follicles. Consequently, AMH levels are 
correlated with ovarian reserve, declining towards menopause when the oocyte pool is 
exhausted. A previous genome-wide association study identified three genetic variants in and 
around the AMH gene that explained 25% of variation in AMH levels in adolescent males but 
did not identify any genetic associations reaching genome-wide significance in adolescent 
females. To explore the role of genetic variation in determining AMH levels in women of late 
reproductive age, we carried out a genome-wide meta-analysis in 3,344 pre-menopausal 
women from five cohorts (median age 44–48 years at blood draw). A single genetic variant, 
rs16991615, previously associated with age at menopause, reached genome-wide significance 
at P=3.48×10-10, with a per allele difference in age-adjusted inverse normal AMH of 0.26 SD 
(95% CI [0.18,0.34]). We investigated whether genetic determinants of female reproductive 
lifespan were more generally associated with pre-menopausal AMH levels. Genetically-
predicted age at menarche had no robust association but genetically-predicted age at 
menopause was associated with lower AMH levels by 0.18 SD (95% CI [0.14,0.21]) in age-
adjusted inverse normal AMH per one-year earlier age at menopause. Our findings provide 






Anti-Müllerian hormone (AMH) is a member of the transforming growth factor-beta 
superfamily that regulates the growth and development of ovarian follicles in females and is 
required for sexual differentiation in the fetus, causing regression of the Müllerian ducts 
during testis development (1). In males, AMH is required for testes development and function 
and levels increase rapidly shortly after birth, peaking at 6 months of age, and then decline to 
low levels in during puberty (2). In women, AMH is produced by the granulosa cells of 
growing follicles and levels are correlated with the number of growing follicles and are used 
as a clinical measure of ovarian reserve (3). AMH levels increase in women from birth until 
their 20s, before declining gradually with age until levels are undetectable after menopause 
when ovarian reserve is exhausted (1, 3–6). Since AMH levels are stable throughout the 
menstrual cycle, they can be used as a measure of fertility in women of late reproductive age 
and to predict response to fertility treatment (7).  
AMH levels vary widely between women and genetic variation is thought to be important, 
though few genetic studies have been conducted. Rare AMH mutations have been found with 
functional effects on AMH signalling (8, 9), while polymorphisms in AMH or the gene 
coding for its receptor, AMHR2, have been associated with response to ovarian stimulation, 
infertility, follicle recruitment, primary ovarian insufficiency and polycystic ovary syndrome 
in candidate gene studies (10).  
A previous genome-wide association study (GWAS) in 1,360 adolescent males and 1,455 
adolescent females from a single cohort identified three genetic variants in and around the 
AMH gene that were independently associated with higher levels of AMH in adolescent 
males (P=2×10-49 to P=3×10-8 for each variant when jointly included in the regression model) 




females (P=8×10-4 to P=0.9 for each variant when jointly included in the regression model), 
with considerably weaker effect estimates than in males. For all three variants there was 
strong statistical evidence of a sex difference (PHET=3×10
-4 to PHET=6×10
-12), with the three 
cumulatively explaining 24.5% of the variation in AMH levels in males compared with 0.8% 
in females. No cohorts were available for replication of this initial study and it is unknown 
whether the weak or absent association in adolescent females persists into older ages, as 
would be expected since differences in ovarian decline result in variation in AMH levels 
between women. 
We undertook a GWAS meta-analysis of 3,344 women from five cohorts – the Generations 
Study, Sister Study, Nurses’ Health Study, Nurses’ Health Study II and Avon Longitudinal 
Study of Parents and Children (ALSPAC) − to investigate genetic determinants of AMH 
levels in pre-menopausal women of late reproductive age (median age at blood draw 44–48 
years). We aimed to identify novel genetic variants associated with AMH levels and to 
explore the effects of published genetic variants associated with AMH levels in previous 





AMH is associated with a single significant signal in a known menopause locus 
In our genome-wide meta-analysis (Table 1), a single genetic variant in the MCM8 gene at 
20p12.3 reached genome-wide significance at P<5×10-8 (rs16991615, P=3.48×10-10) (Figure 
1,  Supplementary Figure 1). Within each of the five genotyped cohorts, we inverse-normally 
transformed AMH (to ensure normality of the residuals in the association analysis) and tested 
the association of over 11 million autosomal genetic variants imputed to HRC r1.1 2016 (12) 
adjusted for age and genetic relatedness (13). We performed inverse variance weighted meta-
analyses of the genome-wide results from the five cohorts, filtering our results to include only 
variants present in three or more of the five cohorts analysed, resulting in a total of 8.4 
million variants in the final results dataset (summary statistics to be made available through 
the EMBL-EBI GWAS catalogue at https://www.ebi.ac.uk/gwas/summary-statistics). A total 
of 242 variants had P<1×10-5, resulting in 24 signals following distance-based clumping of 
variants within 500kb, with the top ten signals presented in Table 2. The minor A allele of 
rs16991615 increased age-adjusted inverse normal AMH by 0.26 SD per allele (95% CI 
[0.18,0.34], P=3.48×10-10) (Table 2). 
 
Variants previously shown to be strongly associated with AMH levels in adolescent males 
had weak effects in pre-menopausal adult women in our study 
For three genetic variants in and around the AMH gene that were previously found to be 
independently associated with higher levels of AMH in adolescent males (11), we estimated 
the effects in pre-menopausal women when the variants were jointly included in the 
regression model (joint model), by carrying out approximate conditional analyses using the 




estimates, we generated effect estimates for age-adjusted inverse normal AMH in the 
adolescent males and females from the original study sample (ALSPAC offspring), since 
results from the original study were unadjusted and presented in natural log-transformed 
AMH.  
The effect estimates from the joint model for the three published genetic variants were 
directionally concordant across adolescent males and females (ALSPAC offspring cohort) 
and the pre-menopausal women in the current study (from five cohorts including ALSPAC 
mothers), but had about one-fifth of the effect on the level of AMH compared with the effect 
in adolescent males (PHET<0.001) (Figure 2). The weak or null effect sizes for rs4807216, 
rs8112524 and rs2385821 were similar in adolescent and pre-menopausal females (PHET>0.05 
for all). Genetic variant rs2385821 had the strongest effects in females of the three variants 
from the previous publication (11), but did not reach genome-wide significance in pre-
menopausal females (for joint model, per allele difference in age-adjusted inverse normal 
AMH of 0.27 SD (95% CI [0.13,0.41]), P=4.0×10-5) (Supplementary Table 1). 
 
Genetic variants for early menopause are associated with reduced levels of AMH  
Since the only genetic variant to reach genome-wide significance in our study (rs16991615) 
has previously been reported as associated with menopause timing (15–17), we investigated 
the association of AMH levels with all 56 genetic variants associated with menopause timing 
(17). The effect estimates of these genetic variants on AMH level were positively correlated 
with the published effects on age at menopause (r=0.83) and there were consistent directions 
of effect for 50/56 variants (P=1×10-9 for binomial sign test; χ256=194.39, P=4×10
-17 for 




obvious outliers among the 56 menopause timing variants and generally variants with large 
effects on age at menopause also had large effects on AMH levels.  
Two-sample Mendelian randomization analysis by inverse variance weighted (IVW) and 
Egger estimation supported a causal relationship between genetically-predicted age at 
menopause and pre-menopausal AMH level (Figure 3, Supplementary Table 2). For a one-
year increase in genetically-predicted age at menopause, age-adjusted inverse normal AMH 
was increased by 0.18 SD (95% CI [0.14,0.21]) with no horizontal pleiotropy detected by 
Egger analysis (in Egger analysis, 0.20 SD (95% CI [0.13,0.27]) age-adjusted inverse normal 
AMH per a one-year increase in genetically-predicted age at menopause one-year increase in 
genetically-predicted age at menopause, P-intercept=0.49). This relationship remained 
similar even when rs16991615 was excluded from the analysis (Supplementary Table 3). 
 
Genetic variants for age at menarche are not associated with AMH levels 
We investigated the effect of genetic variants associated with age at menarche on AMH 
levels (18), since menarche marks the start of cyclic selection of ovarian follicles from the 
growing follicle pool. We identified 327 of 389 published independent signals (18) in our 
meta-analysis results. For the 327 variants, there was little correlation between the published 
effect on age at menarche and the effect on AMH levels (r=-0.05) and the directions of 
effects were not consistent, with 158/327 (48%) in the same direction (P=0.58 for binomial 
sign test; χ2327=328.62, P=0.46 for global chi-squared test of association) (Figure 3, 
Supplementary Table 4). Two-sample Mendelian randomization analysis by IVW and Egger 
estimation found no causal relationship between age at menarche and AMH level (difference 




at menopause was for IVW, -0.05 SD (95% CI [-0.12,0.02]) and for Egger, -0.03 SD (95% CI 
[-0.22,0.15], P-intercept=0.87) (Figure 3, Supplementary Table 3). 
 
Genetic variant for follicle-stimulating hormone levels is not associated with AMH levels 
Since levels of follicle-stimulating hormone (FSH) and luteinising hormone (LH) rise around 
menopause, we tested the association of a genetic variant at the FSHB locus that affects levels 
of these hormones (19) with AMH levels in pre-menopausal women. The FSHB promoter 
polymorphism (rs10835638; -211G>T) was not associated with AMH levels (per allele 
difference in age-adjusted inverse normal AMH of 0.01 SD (95% CI [-0.05,0.07]), P=0.79). 
 
Sensitivity analysis 
Results for genetic variants with P<5×10-5 in the main analysis were well-correlated whether 
we adjusted for age or not (r=0.99) (Supplementary Figure 2), used our favoured inverse 
normal transformation or a natural log transformation (as in reference (11)) (r=1.00) 
(Supplementary Figure 3), and when we excluded women whose AMH level was imputed as 






Our results indicate that variation in AMH levels in pre-menopausal women is contributed to 
by the underlying biology of ovarian reserve, as shown by the correlation between 
genetically-predicted age at menopause and AMH levels, supporting the use of AMH as a 
means of measuring ovarian reserve. The only signal passing genome-wide significance in 
our analyses was rs16991615 in MCM8, a published menopause timing variant (15–17), with 
the same allele associated with earlier menopause and lower AMH levels. Genome-wide 
analyses of menopause timing, a proxy measure for ovarian reserve, have identified 56 
genetic variants and highlighted the importance of DNA damage response pathways during 
follicle formation in utero and for follicle maintenance during a woman’s lifetime (17). 
Additionally, 389 genetic variants have been identified for menarche timing, the age at which 
cyclic selection of ovarian follicles from the pool of growing, AMH-producing follicles starts 
(18). Therefore, it is plausible that genetic determinants of menarche and menopause timing 
could affect ovarian reserve and influence AMH levels in pre-menopausal women, many 
years prior to menopause. For genetic variants associated with age at menopause, the 
published effect estimates were positively correlated with the effects on AMH levels and 
there was evidence of a causal relationship between genetically-predicted earlier menopause 
and lower pre-menopausal AMH levels, which remained even when rs16991615 was 
excluded. We did not find any association between genetically-predicted age at menarche and 
pre-menopausal AMH levels. We interpret these results as suggesting that AMH levels in 
pre-menopausal women are determined by declining ovarian reserve as a result of 
reproductive ageing but not menarche timing, and that women with lower AMH are nearer to 
the end of their reproductive lifespan.  
Variant rs16991615 has previously been found to be associated with differences in 




(E341K), which is required for homologous recombination (20). Other mutations in MCM8 
causing reduced double strand break repair have been found in women with premature 
ovarian failure (21) and follicle development is arrested at an early stage in MCM8 knockout 
mice (22). Pathway analysis has shown that the menopause timing variants identified from 
genome-wide analyses are enriched for genes involved in DNA damage response, including 
double-strand break repair during meiosis, suggesting that the genetic determinants of age at 
menopause act during ovarian follicle formation or maintenance, potentially affecting ovarian 
reserve from before birth until menopause (18). Therefore, it seems likely that rs16991615 
affects AMH levels through differences in ovarian reserve.  
Although the three published GWAS signals in and around the AMH gene (11) did not reach 
genome-wide significance when jointly included in the regression analysis, they did show 
directional consistency and were nominally associated in the pre-menopausal women in our 
study. The previous GWAS of adolescent females included fewer samples (n=1,455) than our 
analysis (n=3,344), hence we were better powered to detect the effects of these variants in 
females. The three published variants for AMH had smaller effects in pre-menopausal 
women compared with adolescent males but were consistent with the associations seen 
previously in adolescent females. The strongest signal in the GWAS of AMH levels in 
adolescents, rs4807216, was not associated with age at menopause in the most recent 
genome-wide meta-analysis (per allele difference in age-adjusted inverse normal AMH of 
0.05 SD (95% CI [-0.05, 0.15]), P=0.37) (17). Differences in genetic regulation of AMH 
levels in males and females are plausible given AMH’s different function in men and women. 
In males, AMH is required for regression of the Müllerian ducts during testis development in 
the fetus, and is involved in testicular development and function (2). In females, AMH is 
produced by granulosa cells of primary, pre-antral and small antral follicles, inhibiting both 




selection of follicles for growth during the menstrual cycle (3, 7, 23, 24). AMH expression 
starts in utero at 36 week’s gestation, peaking at around 25 years before declining to 
undetectable levels at menopause (3, 5, 7). In our analysis, a polymorphism in the promoter 
of FSHB (-211G>T) that affects FSH levels (25–27) had no effect on AMH levels in pre-
menopausal women, supporting the absence of direct negative feedback of FSH on AMH. 
AMH levels vary widely between women (6), reflecting factors such as variation in ovarian 
reserve, age and ethnicity (13). We controlled for age and ethnicity by adjusting for age and 
restricting our analyses to genetically European individuals. Adjustment for age will remove 
a source of variation in AMH level, the effect of the decrease in the primordial follicle pool 
with age, highlighting the effect of genetic variants responsible for variation in the initial size 
of the primordial follicle pool or that either accelerate or protect against loss of ovarian 
reserve with age. 
We would have been unable to detect low frequency variants or those with a smaller effect 
size since we were only powered (>80%) to detect a variant with a MAF of 5% and an effect 
of 0.36 SD or greater in the sample size analysed. We were unable to evaluate the effect of 
time from study participation to menopause on our results, to investigate whether the 
association of the menopause variants was modified by proximity to menopause, since we did 
not have sufficient follow-up data. Future analysis should consider stratifying by participants’ 
time to menopause. However, such analyses would require large numbers of women who had 
pre-menopausal AMH measurements (AMH levels are generally undetectable post-
menopause), recorded age at menopause and varying times of follow-up since age at 
menopause. We are not aware of any such study currently but with continued follow-up of 




This study confirms genetically that AMH levels are a marker for ovarian decline and 
reproductive ageing in pre-menopausal women. In addition to its use as a marker of fertility, 
there is evidence that AMH is a biomarker of breast cancer risk in pre-menopausal women. In 
a recent study, odds of pre- and postmenopausal breast cancer were 60% higher in women in 
the highest quartile of AMH level compared with the lowest, even after adjusting for 
potential confounders such as age (28). Our study suggests that these effects could be 
mediated through preserved ovarian reserve, or a correlate of ovarian reserve, as a result of 
delayed reproductive ageing, supported by findings from a large scale genomic analysis that 
showed a causal effect of later menopause on increased risk of breast cancer by 6% per year 
(17) and strong epidemiological evidence that later age at menopause increases risk of breast 
cancer (29). Our study provides genetic evidence that underlying biological factors 
responsible for reproductive ageing contribute to AMH levels in pre-menopausal women and 






Materials and Methods 
Studies included  
The central analysis team at University of Exeter Medical School coordinated data collection 
from the five studies. We included 3,344 women who had pre-menopausal AMH levels 
measured, who were participants in the Generations Study (30), the Sister Study (31), the 
Nurses’ Health Study, the Nurses’ Health Study II (32) and ALSPAC (33–35) (Table 1) 
(Supplementary Information). For the Generations Study, the Sister Study and the Nurses’ 
Health Studies, genotype and phenotype data were provided to the central analysis team for 
quality control, cleaning and analysis. For the ALSPAC study, quality control and genotype-
phenotype analyses were undertaken in house and summary descriptive, GWAS and 
sensitivity analyses statistics were provided to the central analysis team for meta-analysis.  
 
Genetic data 
In the Generations Study, Sisters and the Nurses’ Health Studies, samples were genotyped on 
the OncoArray array (Table 1). For the Nurses’ Health Studies, a further 225 samples were 
genotyped on an Illumina array. For each cohort and array type, data were cleaned using a 
standard quality control process in PLINK v1.9 (www.cog-genomics.org/plink/1.9/) (36). 
SNPs were removed if they were poorly genotyped (missing in >5% samples) or were not in 
Hardy-Weinberg equilibrium (P<1×10-6). Samples were removed if they were poorly 
genotyped (missing >5% SNPs), were a sex mismatch or were outliers in terms of 
heterozygosity. Within each cohort, samples that were related to each other as 3rd degree 
relatives or closer were identified and the sample with the greater proportion of missing SNPs 
was removed. Principal component analysis was carried out in FlashPCA in order to identify 




aligned to the correct strand in HRC v1.1 were used for imputation. Genotypes for 
chromosomes 1–22 were phased using SHAPEIT and imputed to HRC r1.1 2016 using the 
University of Michigan Imputation Server (https://imputationserver.sph.umich.edu/) (12, 37, 
38).  
ALSPAC mothers were genotyped using the Illumina Human660W-Quad array at Centre 
National de Génotypage (CNG) and genotypes were called with Illumina GenomeStudio. 
Quality control was performed in PLINK v1.07 (39) by removing poorly genotyped SNPs 
(missing in >5% samples), not in Hardy-Weinberg equilibrium (P<1×10-6), or that had 
MAF<1%. Samples were removed if they were poorly genotyped (missing >5% SNPs), had 
indeterminate X chromosome heterozygosity or extreme autosomal heterozygosity. Samples 
showing evidence of population stratification were identified by multidimensional scaling of 
genome-wide identity by state (IBS) pairwise distances using the four HapMap populations 
as a reference, and then excluded (IBS>0.125). Haplotypes were estimated using SHAPEIT 




For the Generations Study, Sister Study and the Nurses’ Health Studies, AMH levels were 
measured in blood samples taken from pre-menopausal women before breast cancer 
incidence by the individual studies as part of a collaborative, prospective study of AMH and 
breast cancer risk (28). Serum AMH levels were measured using an ultrasensitive ELISA 
(Ansh Labs, Webster, TX) (Sister Study) or a picoAMH enzyme-linked immunoabsorbent 
assay (Ansh Labs, Webster, TX) (Generations Study and the Nurses’ Health Studies, and 




were taken following a standardized protocol in women who attended a series of clinic 
assessments starting about 18 years after the index pregnancy and fasted (overnight or a 
minimum of 6 hours for those assessed in the afternoon) serum AMH levels were measured 
using the Beckman Coulter AMH Gen II ELISA assay (34, 35). 
For samples with AMH below the lower limit of detection, levels were imputed: for the 
Generations Study, the value was the midpoint between zero and the lower limit of detection 
(0.00821 pmol/L); for the Sister Study, missing values were imputed as 0.0015 ng/mL to be 
consistent with the previous analysis (28); for ALSPAC, measured AMH values <0.01 ng/mL 
were imputed to be 0.01 ng/mL. A small number of women (n=24) in the Nurses’ Health 
Studies with AMH below the lower limit of detection (2.038 pg/mL) were excluded from the 
analyses. For all studies, measured values of AMH were converted to pmol/L using 1 
pg/mL=0.00714 pmol/L and 1 ng/mL= 7.14 pmol/L. AMH was transformed by inverse 
normal transformation, in which the rank of the AMH value was converted to the z-score for 
the corresponding quantile of a standard normal distribution. This was done in order to 
approximate a normal distribution to ensure normality of the residuals in the association 
analysis and to rank the measured AMH values from each cohort to a consistent scale, 
avoiding the issue of consistently higher/lower AMH measurements due to the assay used. 
AMH levels for each study are summarised in Table 1. 
 
Genome-wide analysis 
Genome-wide linear regression analysis was carried separately for each of the five cohorts 
for autosomal genetic variants with imputation quality>0.4 assuming an additive model. Age 
at time the blood sample was taken was included as a covariate since age is known to be 




exploratory analysis (median age in each study is summarised in Table 1). For the 
Generations Study, Sisters and Nurses’ Health Study, analysis was carried out using 
GEMMA 0.94.1 (41), which calculates a genetic relationship matrix to account for cryptic 
relatedness and population stratification between the samples. The genetic relationship matrix 
was created from a pruned list of uncorrelated SNPs created in PLINK 1.9 (www.cog-
genomics.org/plink/1.9/) (36) using --indep-pairwise, excluding regions of long range linkage 
disequilibrium, based on variants with MAF>0.01, excluding variants with r2>0.5 (window 
size of 1000, calculated in steps of 50). The analysis included approximately 11.8 million 
genetic variants for the Generations Study, 12.9 million for the Sister Study, 12.3 million for 
Nurses’ Health Study OncoArray and 11.1 million for Nurses’ Health Study Illumina. For 
ALSPAC, the analysis was carried out in SNPTESTv2.5 (42) adjusting for the top ten 
principal components of ancestry which resulted in approximately 14.7 million SNPs.  
Standard error weighted meta-analysis of the individual GWAS results was carried out in 
METAL (version 2011-03-25) (43) with genomic control applied to account for inflation due 
to any remaining population stratification. Genetic variants included in the meta-analysis had 
imputation>0.4 and minor allele count>5 (calculated from allele frequencies), resulting in a 
total of 11.2 million autosomal SNPs that were analysed. Approximately 8.4 million variants 
were present in three or more of the five datasets analysed and were included in our final 
results. We identified independent signals as being suggestive of genome-wide association if 
they had P<1×10-5 and were more than 500kb from another signal; from these, we identified 
signals reaching genome-wide significance at P<5×10-8. 
Manhattan and quantile−quantile plots for the genome-wide association results were created 
using the package qqman (44) in R (The R Foundation for Statistical Computing). 
LocusZoom v1.4 (45) was used to plot the association statistics with age-adjusted inverse 




Linkage disequilibrium was calculated in PLINK v1.9 (www.cog-genomics.org/plink/1.9/) 
(36) from best guess genotypes for 1000 Genomes Phase 3/HRC imputed variants in 
~340,000 unrelated Europeans from the UK Biobank study (46). 
 
Generation of age-adjusted inverse normal effect estimates in ALSPAC offspring cohort 
For three published genetic variants that were associated with AMH levels in adolescent 
males in the ALSPAC offspring cohort (11), we generated effect estimates for age-adjusted 
inverse normal transformed AMH in the original study sample, since the original published 
estimates were unadjusted and presented in natural log-transformed AMH.  Analyses were 
carried in SNPTEST v2.5 (42) adjusting for the top ten principal components of ancestry and 
age and excluding the most extreme 1% of measured AMH values, resulting in 1,312 males 
and 1,421 females from the ALSPAC offspring cohort for analysis. Other methods were as 
described previously (11). 
 
Estimation of joint effects of variants in and around the AMH gene 
We used GCTA (version 1.25.0), using the command --cojo-joint (14), to carry out an 
approximate conditional analysis to estimate the joint effects of three genetic variants in and 
around the AMH gene (11). Linkage disequilibrium between the variants was estimated using 
a random sample of 8,569 white British individuals from the UK Biobank May 2015 interim 
release of imputed genetic data (47). 
 




We compared the published effect estimates for 56 genetic variants associated with age at 
menopause (17) and 389 genetic variants associated with age at menarche (18) with their 
effects on AMH level in our analysis, by carrying out a Binomial sign test of directional 
consistency and calculating Pearson correlation coefficients.  To explore whether age at 
menopause or age at menarche causes differences in AMH levels, we used the genetic 
variants associated with menopause and menarche timing as instruments for age at 
menopause and age at menarche in two-sample Mendelian Randomization analyses. We used 
the Stata package mrrobust (48) to carry out inverse variance weighted (IVW) and Egger 
(which takes account of horizontal pleiotropy (49)) analyses. Analyses were carried out in 
Stata MP 13.0 and Stata SE 14.2 (StataCorp, TX, USA). 
 
Sensitivity analysis 
The genome-wide analysis was repeated without adjustment for age, using a natural log 
transformation (to be consistent with the previously published GWAS (11)), and also 
excluding women whose AMH level was imputed as it was below the lower limit of 
detection. We compared effect sizes in the main analysis with estimates from these alternate 
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Legends to Figures 
Figure 1. Association statistics with age-adjusted inverse normal AMH for variants within 
500kb of rs16991615 (chr20:5948227) showing linkage disequilibrium with the top variant. 
Note: Linkage disequilibrium shown is in unrelated Europeans in UK Biobank. 
 
Figure 2. Comparison of effect sizes of three genetic variants previously associated with 
higher levels of AMH (11) when jointly included in the regression model: effect in adolescent 
males and females from the ALSPAC offspring cohort (previous study, Perry et al 2016 (11)) 
and pre-menopausal women (current study). 
Note: Effect is difference in mean AMH per allele in standard deviations of age-adjusted 
inverse normal AMH. 
ES=effect size. 
 
Figure 3. Inverse variance weighted and Egger two-sample Mendelian randomization 
analyses of the effect of genetically-predicted (a) age at menopause and (b) age at menarche 
on age-adjusted inverse normal AMH levels in pre-menopausal women.  
Note: Difference in mean age-adjusted inverse-normal AMH per one-year increase in 








Table 1. AMH levels and age of women in each of the five cohorts included in the genome-
wide analysis.  
  Median (interquartile range) 
Study  n AMH (pmol/L) Age (years) at 
blood draw  
Generations Study 379 3.9 (0.8,11.7) 44 (40,48) 
Sister Study 438 1.2 (0.1,6.0) 48 (45,51) 
Nurses’ Health Studies 
(Illumina)1 
225 5.5 (1.5,12.4) 45 (42,48) 
Nurses’ Health Studies 
(OncoArray) 1 
417 6.7 (2.5,14.9) 44 (41,46) 
Avon Longitudinal Study of 
Parents and Children 
1,885 2.0 (0.4, 5.2) 46 (44,49) 
Total 3,344   
1Data from the Nurses’ Health Study and Nurses’ Health Study II were combined and 






Table 2. Top ten signals from the genome-wide analysis of age-adjusted inverse normal AMH 






























































































Beta=difference in mean age-adjusted inverse normal AMH (SD) per allele. 
Chr=chromosome; Dir. = positive (+) or negative (-) direction of effect in Avon Longitudinal 
Study of Parents and Children, Sister Study, Generations Study, Nurses’ Health Studies 
(OncoArray), Nurses’ Health Studies (Illumina) respectively, with “?” indicating that the 
variant was absent; EA=effect allele; EAF=weighted average effect allele frequency across 
the studies; Het. P=P-value from Cochrane’s Q-test of heterogeneity of effects across the 
studies; Imp. qual = mean imputation quality across the studies; Pos=position in 










CNG=Centre National de Génotypage 
EA=effect allele 
EAF=weighted average effect allele frequency across the studies 
ES=effect size 
FSH=follicle-stimulating hormone 
GWAS=genome-wide association study 
Het. P=P-value from Cochrane’s Q-test of heterogeneity of effects across the studies 
IBS=identity by state 
Imp. qual = mean imputation quality across the studies 
IVW=inverse variance weighted 
LH=luteinising hormone 
OA=other allele 
PCOS=polycystic ovary syndrome 
Pos=position in hg19/GRCh37 
SD=standard deviation 
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SE=standard error 
 
 
 
 
 
